OBJECTIVE: Fetal growth restriction is associated with stillbirth and other adverse pregnancy outcomes, and use of the correct weight standard is an essential proxy indicator of growth status and perinatal risk. We sought to assess the performance of two international birthweight standards for their ability to identify perinatal morbidity and mortality indicators associated with small for gestational age (SGA) infants. STUDY DESIGN: This retrospective cohort study used data from a multi-center quality initiative including a multi-ethnic dataset of 125826 births from 2012e2017. Of the singleton term births available, 96142 had complete outcome data including stillbirth, neonatal death, 5-minute Apgar, glucose instability and need for newborn transfer to a higher level of care or NICU admission. The customized (GROW) and st (IG21) birthweight standards were applied to determine SGA according to their respective methods and formulae. Associations with adverse outcomes were expressed as odds ratios (OR) with 95% confidence intervals (CI) and population attributable risk (PAR). RESULTS: GROW classified 10479 (10.9%) and IG21 classified 4282 (4.5%) pregnancies as SGA, respectively. For all of the outcomes assessed, GROW identified more SGA infants with adverse outcomes than IG21 did, including more with stillbirth, perinatal death, low Apgar (<7), glucose instability and transfers to a higher level of care (Table 1 ). In the case of stillbirth, 14 of the 29 cases (48%) that were SGA by either method were identified as SGA by GROW only and not by IG21. Similarly, additional cases of all other adverse outcome indicators were identified by GROW as SGA, while only in one category (glucose instability) did IG21 identify 7 of 315 cases (2.2%) which were not identified as SGA by GROW. CONCLUSION: Customized assessment using GROW results in increased identification of small for gestational age babies that are at significantly increased risk of an array of adverse pregnancy outcomes.
196 An enhanced recovery after surgery pathway for cesarean delivery decreases hospital stay and cost Emily E. Fay, Laurent Bollag, Carlos Delgado, Leah M. Savitsky, Elizabeth Mills, JoAnn L. Slater, Jane Hitti University of Washington, Seattle, WA OBJECTIVE: Enhanced recovery after surgery (ERAS) programs provide a multidisciplinary, evidence-based approach to the care of surgical patients. They have been shown to decrease postoperative length of stay and cost in several surgical specialties but have not been well studied in obstetric patients undergoing cesarean delivery (CD). We hypothesized that implementation of an ERAS CD pathway would decrease postoperative length of stay and direct cost compared to historical controls. STUDY DESIGN: We conducted a retrospective cohort study comparing postoperative length of stay and direct cost among women on the ERAS CD pathway in the first year of implementation (4/1/2017-3/ 31/2018, n¼531) compared to historical controls (3/1/2016-2/28/ 2017, n¼661). Women with pregestational diabetes on insulin prior to pregnancy, preeclampsia with severe features, and those with complex pain needs were excluded from baseline and implementation groups. ERAS CD pathway participation was determined by order set usage. Analysis was stratified for women undergoing planned (no labor, n¼530) and unplanned (labor, n¼662) CD. Demographic and clinical characteristics, postoperative length of stay and direct cost for the baseline and implementation groups were compared using c 2 and t-tests. RESULTS: During the first year of implementation, 531 (83%) of 640 eligible women were included in the ERAS CD pathway. Body mass index was marginally higher in the baseline group for unplanned CD (32.57 vs. 31.47, p¼0.049). There were no other significant differences in demographic or clinical characteristics between baseline and implementation groups. Compared to baseline, implementation of the ERAS CD pathway resulted in a significant decrease in postoperative length of stay by 7.8% or 4.86 hours overall (p<0.001) and for both planned and unplanned CD (Table 1) . Total postoperative cost decreased by 8.4% or $642.85 per patient overall (p<0.001) and for both planned and unplanned CD (Table 1) . There were no significant differences in readmission rates. CONCLUSION: Implementation of an ERAS program for women having planned or unplanned CD was associated with significantly decreased postoperative length of stay and significant cost-savings per patient, without increase in hospital readmissions.
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